List of Excipients in Branded Drug GLYXAMBI

Last updated: August 9, 2026

Glyxambi is a fixed-dose oral combination of empagliflozin and linagliptin used with diet and exercise to improve glycemic control in adults with type 2 diabetes. Its excipient strategy is conventional for immediate-release film-coated tablets, which limits differentiation based solely on inactive ingredients but creates opportunities in lactose reduction, tablet robustness, swallowability, supply-chain efficiency, and alternative combination formats. Commercial opportunity is concentrated in generic substitution, regional licensing, and reformulated diabetes combinations rather than biosimilar competition.

Glyxambi Excipient Strategy and Commercial Opportunities

What is Glyxambi and how is it formulated?

Glyxambi contains two active pharmaceutical ingredients:

Product strength	Empagliflozin	Linagliptin	Dosage form
Glyxambi 10/5 mg	10 mg	5 mg	Film-coated tablet
Glyxambi 25/5 mg	25 mg	5 mg	Film-coated tablet

The product is marketed by Boehringer Ingelheim and Eli Lilly. Empagliflozin is a sodium-glucose cotransporter 2, or SGLT2, inhibitor. Linagliptin is a dipeptidyl peptidase-4, or DPP-4, inhibitor. The FDA approved Glyxambi in 2015 as an adjunct to diet and exercise for adults with type 2 diabetes who require both agents or need additional glycemic control [1].

Glyxambi is an immediate-release, oral, film-coated tablet. The formulation uses conventional pharmaceutical excipients associated with powder flow, granulation, compression, lubrication, and film coating.

Which excipients are used in Glyxambi tablets?

The FDA-approved labeling identifies the following inactive ingredients or excipient classes for Glyxambi:

• Mannitol
• Pregelatinized starch
• Corn starch
• Copovidone
• Magnesium stearate
• Film-coating materials, including hypromellose, polyethylene glycol, titanium dioxide, talc, and colorants

Colorants differ by strength. The 10/5 mg and 25/5 mg tablets use different visual identification schemes, including iron oxide-based pigments [1,2].

The formulation is designed for rapid oral disintegration and immediate release rather than extended release, enteric protection, gastroretention, or modified absorption. The excipient system does not indicate a technically complex delivery platform.

What is the strategic role of each Glyxambi excipient?

Mannitol

Mannitol can provide bulk, acceptable mouthfeel, and improved powder-handling characteristics. It is often selected when a formulation requires a relatively non-hygroscopic diluent or a cleaner sensory profile than some grades of lactose.

For Glyxambi, mannitol supports tablet mass and processability while avoiding dependence on a single filler system. A generic manufacturer could evaluate mannitol grade, particle size, and direct-compression performance as part of a bioequivalence and manufacturing strategy.

Pregelatinized starch and corn starch

Starches perform multiple functions. They can act as fillers, binders, and disintegrants, depending on grade and concentration. Pregelatinized starch improves compactibility, while corn starch can promote tablet breakup after ingestion.

The combination provides a relatively low-cost route to immediate release. The principal development risks are tablet hardness, friability, disintegration time, and dissolution consistency across commercial-scale compression equipment.

Copovidone

Copovidone is a binder used to improve granule and tablet cohesion. It can also assist the distribution of low-dose active ingredients, which is important because linagliptin represents only 5 mg of each Glyxambi tablet.

Uniform distribution of linagliptin is a critical quality attribute. A generic formulation that changes granulation or blending conditions must demonstrate acceptable content uniformity and dissolution for both active ingredients.

Magnesium stearate

Magnesium stearate is the lubricant. It reduces sticking and ejection force during compression. Excessive lubrication can slow wetting and dissolution, particularly when hydrophobic lubricant coats other particles.

This creates a practical formulation-control issue. The generic developer must control lubricant concentration, blending time, shear, and order of addition. Magnesium stearate is inexpensive, but its processing window can affect commercial-scale reproducibility.

Film-coating excipients

The coating provides color, product identification, protection from handling, and improved swallowability. Hypromellose is the primary film-forming polymer. Polyethylene glycol acts as a plasticizer. Talc can improve coating processability, while titanium dioxide and iron oxides provide opacity and color.

A generic manufacturer has considerable flexibility in coating composition if the resulting product meets appearance, stability, dissolution, and bioequivalence requirements. The coating is therefore more likely to create manufacturing and branding opportunities than strong composition-of-matter differentiation.

What formulation opportunities exist for Glyxambi generics?

The strongest opportunities are incremental. Glyxambi does not appear to require a novel delivery technology, but its two-active-ingredient formulation creates several development targets.

Low-lactose or lactose-free positioning

The disclosed Glyxambi excipient profile relies on mannitol and starches rather than a dominant lactose-based filler system. A generic developer can preserve that approach or develop a lactose-free formulation with alternative polyols, microcrystalline cellulose, silicified microcrystalline cellulose, or coprocessed excipients.

A lactose-free product may have commercial value in selected markets, although the label benefit must be supported by a meaningful patient or prescriber proposition. The opportunity is stronger where local procurement systems favor differentiated products or where excipient restrictions affect market access.

Smaller tablets

Tablet size is commercially relevant because patients with type 2 diabetes often take multiple chronic medicines. A smaller Glyxambi tablet could improve swallowing and adherence.

Size reduction must balance:

• The 5 mg linagliptin dose and content uniformity
• Empagliflozin loading at the 25 mg strength
• Compression behavior
• Disintegration
• Coating weight
• Mechanical strength during packaging and transport

High-density excipients, coprocessed fillers, or optimized granulation can reduce tablet volume. A smaller tablet is not automatically patentable, but it can support a product-line and procurement strategy.

Direct compression

Direct compression could reduce unit operations, water exposure, drying costs, and manufacturing time. It may also improve scalability if the active ingredients and excipients have suitable flow and compactibility.

The main risks are segregation between the two active ingredients, low-dose linagliptin distribution, and sensitivity to lubricant blending. A wet-granulated process may provide better uniformity but increase energy use and process complexity.

Robustness under high-volume distribution

Diabetes medicines are distributed through retail, mail-order, hospital, and public procurement channels. A formulation with improved friability, reduced dusting, and better stability under temperature and humidity excursions can lower packaging and complaint costs.

Blister packaging may provide stronger moisture protection than high-density polyethylene bottles, although it can increase packaging cost. The commercial choice depends on geography, distribution conditions, and reimbursement economics.

Alternative dosage forms

Potential alternatives include:

• Orally disintegrating tablets
• Sprinkleable granules
• Mini-tablets
• Dose-flexible combination packs
• Calendar blister systems

The clinical value of these formats is constrained by Glyxambi’s adult target population and the need to preserve the pharmacokinetic performance of both active ingredients. An orally disintegrating version could improve administration for patients with dysphagia, but it would require a new formulation and a supporting regulatory pathway.

What patents protect Glyxambi and its formulation?

The principal intellectual-property exposure is associated with the active ingredients, combination use, manufacturing processes, and product-specific formulations. The commercial assessment should separate four categories:

IP category	Strategic relevance
Empagliflozin compound patents	Core protection for the SGLT2 inhibitor
Linagliptin compound patents	Core protection for the DPP-4 inhibitor
Combination patents	Protection for coadministration or fixed-dose use
Formulation and process patents	Potential barriers involving tablet composition, granulation, coating, or manufacturing

The FDA Orange Book is the controlling public source for patents listed against approved drug products and for associated patent-use codes [3]. Glyxambi patent analysis must be performed against the current Orange Book entry, relevant patent-family members, terminal disclaimers, pediatric extensions, and litigation history. A patent associated with empagliflozin or linagliptin is not necessarily listed against Glyxambi, and an Orange Book listing does not establish ultimate validity or infringement.

Are formulation patents commercially important for Glyxambi?

Formulation patents are more likely to affect launch timing than to create long-term exclusivity if the claims are narrow. A generic applicant may attempt to design around:

• Specific filler ratios
• Granulation methods
• Lubricant concentration
• Coating composition
• Particle-size requirements
• Dissolution specifications
• Fixed-dose tablet architecture

A formulation patent is commercially stronger when it covers a necessary performance feature, has broad claim scope, and cannot be avoided without compromising bioequivalence or manufacturing economics.

When does Glyxambi lose exclusivity?

Glyxambi’s exclusivity is governed by a combination of regulatory exclusivity and patent rights. The FDA approved the product in 2015, and its five-year new chemical entity exclusivity period has expired. The product therefore can be subject to ANDA competition once applicable listed-patent barriers are resolved [1,3].

Patent expiration cannot be inferred from the approval date alone. It depends on the specific patents listed for Glyxambi, patent-term adjustments, patent-term extensions, pediatric exclusivity, and any litigation settlements. The Orange Book should be reviewed for the current patent expiration dates and use codes before making a launch or investment decision.

Are Paragraph IV challenges possible for Glyxambi?

Yes. Glyxambi is a small-molecule combination product, so an ANDA applicant may use a Paragraph IV certification against listed patents. The applicant must demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable labeling requirements.

A Paragraph IV challenge could target:

• The empagliflozin component
• The linagliptin component
• The fixed-dose combination
• A listed method-of-use patent
• A product-specific formulation patent

The commercial attractiveness of a challenge depends on the remaining market, the number of competing applicants, the enforceability of the listed patents, and the cost of proving bioequivalence for a two-active-ingredient product.

What is the FDA regulatory status and Orange Book position of Glyxambi?

Glyxambi is an FDA-approved prescription drug and is regulated as a small-molecule fixed-dose combination. It is not a biologic and does not use the biosimilar pathway [1,4].

The regulatory route for a generic Glyxambi product is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence and bioequivalence to the reference listed drug.

The Orange Book provides the relevant reference-product designation, patent listings, exclusivity information, and therapeutic-equivalence framework. Orange Book status should be assessed separately from international patent status because approval, patent listing, and generic substitution rules vary by jurisdiction [3].

What biosimilar and generic entry risks exist for Glyxambi?

Biosimilar risk is not applicable because empagliflozin and linagliptin are chemically synthesized small molecules. Generic risk is the relevant competitive threat.

Generic entry scenarios

Scenario	Likely commercial effect
Single generic entrant	Moderate price pressure; originator may retain branded share
Multiple ANDA entrants	Rapid reimbursement and tender-price erosion
Authorized generic	Greater control over channel pricing and contracting
Combination-product competition	Direct erosion of Glyxambi volume
Separate-component substitution	Potential loss of fixed-dose convenience value

The most important competitive risk is substitution with separate empagliflozin and linagliptin products if payers view the fixed-dose combination as interchangeable in economic terms. Glyxambi’s value proposition depends on convenience, adherence, formulary placement, and the relative cost of buying two separate products.

Which companies are positioned to challenge Glyxambi?

Potential challengers include established generic manufacturers with diabetes portfolios, contract development and manufacturing organizations, and regional pharmaceutical companies with ANDA or comparable regulatory capabilities.

The most credible competitors are those that can:

• Develop a two-active-ingredient bioequivalence package
• Control low-dose linagliptin content uniformity
• Manufacture both strengths at scale
• Navigate Orange Book certifications
• Secure active-ingredient supply
• Obtain reimbursement or tender access

Competition may emerge first in the United States through ANDA filings and later through national procedures in Europe, Canada, Japan, India, and other regulated markets. Generic launch timing will differ by jurisdiction because patent linkage and regulatory exclusivity rules are not harmonized.

What licensing and commercial opportunities exist for Glyxambi?

The opportunity is stronger for formulation technology and regional commercialization than for licensing the original product itself.

Excipient and formulation licensing

Technology owners could license:

• Direct-compression platforms for dual-active tablets
• Low-dose content-uniformity processes
• High-density excipient systems
• Moisture-resistant film coatings
• Orally disintegrating or smaller-tablet platforms
• Continuous manufacturing processes
• Robust blister and unit-dose packaging

A licensor with a validated platform can reduce development time for generic or hybrid products. The strongest value is likely to come from process transfer, analytical methods, and scale-up support rather than from a single inactive ingredient.

Regional commercialization

Regional companies may pursue rights to manufacture or market Glyxambi-equivalent products outside the United States. Commercial value will depend on local patent status, reference-product availability, diabetes prevalence, reimbursement, and the presence of competing SGLT2/DPP-4 combinations.

Combination-product portfolio strategy

A manufacturer with empagliflozin, linagliptin, or related diabetes products can use Glyxambi as part of a broader portfolio that includes:

• Empagliflozin monotherapy
• Linagliptin monotherapy
• Empagliflozin/metformin combinations
• Other SGLT2/DPP-4 combinations
• Fixed-dose products with additional glycemic agents

The portfolio approach can improve physician coverage and reduce dependence on a single combination tablet.

How does Glyxambi compare with competing diabetes combinations?

Glyxambi competes with separate SGLT2 and DPP-4 products and with other fixed-dose combinations. Its technical differentiation is limited because it is an immediate-release tablet using standard excipients. Its commercial differentiation comes from combining two branded mechanisms in one tablet.

Dimension	Glyxambi	Separate empagliflozin and linagliptin	Other fixed-dose diabetes combinations
Administration	One tablet	Two tablets	Usually one tablet
Formulation complexity	Moderate dual-active formulation	Lower per product, higher patient pill burden	Varies
Excipient differentiation	Limited	Product-specific	Often limited
Generic development	Requires dual-active equivalence	Separate ANDAs	Depends on combination
Adherence proposition	Convenience advantage	Higher pill burden	Convenience varies
Pricing exposure	Combination-product and component substitution	Component-level competition	Class and payer dependent

Glyxambi’s commercial durability depends more on clinical positioning and contracting than on excipient exclusivity.

What is the revenue exposure and market opportunity?

Boehringer Ingelheim and Eli Lilly do not generally disclose Glyxambi revenue as a standalone line item in public financial reporting. Reported diabetes revenue is typically grouped across multiple products and markets. Product-level revenue therefore cannot be reliably assigned from company-wide disclosures [5,6].

The principal revenue exposure is concentrated in:

• U.S. branded prescription sales
• Formulary positioning
• Combination-product adherence
• Price competition from generic or authorized-generic products
• Substitution with separate components
• International reimbursement and tender markets

For a potential generic entrant, the addressable market should be modeled using prescription volume, net price, payer mix, expected generic discount, launch sequence, and the number of approved competitors. Gross sales estimates without these variables materially overstate commercial value.

How strong is the Glyxambi patent estate?

The estate is strategically important but should not be characterized as strong or weak from the product label alone. Strength depends on claim breadth, remaining term, listing status, validity risk, infringement evidence, and the ability to design around formulation claims.

The most defensible barriers are generally those tied to:

• Core active-ingredient chemistry
• Validated combination claims
• Narrow but commercially necessary manufacturing steps
• Patented uses that match the approved labeling

Excipient-only claims are vulnerable when a generic can replace the excipient without changing clinical performance or regulatory equivalence.

Key Takeaways

• Glyxambi is a 10/5 mg and 25/5 mg immediate-release film-coated tablet containing empagliflozin and linagliptin.
• Its excipient system uses conventional materials, including mannitol, starches, copovidone, magnesium stearate, and film-coating agents.
• The leading formulation opportunities are smaller tablets, direct compression, improved content uniformity, lactose-free positioning, and more robust packaging.
• Glyxambi has small-molecule generic risk, not biosimilar risk.
• Paragraph IV challenges are possible against applicable Orange Book-listed patents.
• Patent exposure must be assessed through the current Orange Book and relevant patent-family records.
• Product-level Glyxambi revenue is not separately disclosed by the sponsors.
• The strongest commercial opportunities are generic development, regional licensing, formulation platforms, and diabetes portfolio integration.

FAQs

Can Glyxambi be reformulated as an orally disintegrating tablet?

Yes, but an orally disintegrating version would require a new formulation-development program, stability data, dissolution assessment, and an applicable FDA regulatory submission. The commercial case would depend on demonstrated swallowing or adherence benefits.

Does Glyxambi contain lactose?

The FDA labeling identifies mannitol and starch-based excipients among the inactive ingredients. A product-specific assessment should rely on the current approved label and package insert because excipient disclosures can differ by strength and market.

Can a generic manufacturer use different excipients from Glyxambi?

Yes. An ANDA generally does not need to duplicate every inactive ingredient. The proposed product must meet applicable pharmaceutical-equivalence, bioequivalence, quality, stability, labeling, and safety requirements.

Is empagliflozin/linagliptin combination therapy protected by method-of-use patents?

It may be covered by listed or unlisted method-of-use claims depending on jurisdiction and patent family. The relevant claims must be compared with the approved indication, patent-use code, and current Orange Book listing.

What is the main manufacturing barrier for a Glyxambi generic?

The principal technical challenge is achieving uniform distribution and reliable dissolution for two active ingredients, particularly the 5 mg linagliptin dose, while maintaining tablet strength, scale-up reproducibility, and regulatory bioequivalence.

References

1. U.S. Food and Drug Administration. (2015). Glyxambi (empagliflozin and linagliptin) prescribing information.
2. National Library of Medicine. (n.d.). Glyxambi: DailyMed drug label.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process.
5. Eli Lilly and Company. (2023). Annual report.
6. Boehringer Ingelheim. (2023). Annual report and financial information.